Cancer Research AACR Conference on Molecular Diagnostics - 2008  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 45, 4167-4174, September 1, 1985]
© 1985 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, D. H.
Right arrow Articles by Grover, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, D. H.
Right arrow Articles by Grover, P. L.

Aberrant Activation of Benzo(a)pyrene in Cultured Rat Mammary Cells in Vitro and following Direct Application to Rat Mammary Glands in Vivo1

David H. Phillips, Alan Hewer and Philip L. Grover

Chester Beatty Laboratories, Institute of Cancer Research, Royal Cancer Hospital, Fulham Road, London SW3 6JB, England

Primary cultures of epithelial cell aggregates and fibroblasts derived from mammary tissue from female Wistar rats were treated with benzo(a)pyrene (BP), and their DNA was isolated and analyzed. At least seven BP-DNA adducts were detected in DNA hydrolysates by high-performance liquid chromatography, none of which had the chromatographic properties characteristic of adducts formed by the putative ultimate carcinogen r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene (anti-BP-7,8-diol-9,10-oxide) or other known electrophilic metabolites of BP. Similar profiles of adducts were obtained from mammary DNA of rats that had been treated with BP by injection into their mammary fat pads. Chromatography on boronate columns indicated that five of the seven adducts contained cis-hydroxyl groups. In contrast, when BP was administered by i.p. injection to female Wistar rats, anti-BP-7,8-diol-9,10-oxide-DNA adducts were detected in each of seven tissues, including mammary gland, that were examined.

1 This study was supported by grants from the United Kingdom Medical Research Council and Cancer Research Campaign.

Received 1/11/85. Revised 4/23/85. Accepted 4/30/85.




This article has been cited by other articles:


Home page
MutagenesisHome page
K.-Y. Seo, A. Nagalingam, M. Tiffany, and E. L. Loechler
Mutagenesis studies with four stereoisomeric N2-dG benzo[a]pyrene adducts in the identical 5'-CGC sequence used in NMR studies: G->T mutations dominate in each case
Mutagenesis, November 1, 2005; 20(6): 441 - 448.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1985 by the American Association for Cancer Research.